Vitamin D Status Determines Cardiometabolic Effects of Cabergoline in Women with Elevated Prolactin Levels: A Pilot Study
Nutrients · 2023
DOI: 10.3390/nu15102303 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nutrients, 2023. Verfasst von Robert Krysiak und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, 40-752 Katowice, Poland. Hauptthemen laut MEDLINE: Hyperprolactinemia, Vitamin D Deficiency, Cardiovascular Diseases. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Silesia in Katowice.
Abstract (Originalsprache)
Both hyperprolactinemia and vitamin D deficiency appear to be associated with increased cardiometabolic risk. This study aimed to determine whether vitamin D status influences the cardiometabolic effects of cabergoline. The study included three matched groups of women with mild to moderate hyperprolactinemia: vitamin D-naive subjects with vitamin D insufficiency (group A), women with vitamin D deficiency/insufficiency successfully treated with vitamin D (group B), and vitamin D-naive individuals with normal vitamin D status (group C). Plasma prolactin, 25-hydroxyvitamin D, estradiol, glucose homeostasis markers, lipids, high-sensitivity C-reactive protein (hsCRP), fibrinogen, homocysteine, and uric acid, as well as the urinary albumin-to-creatinine ratio (UACR), were measured at study entry and after four months of cabergoline treatment. Although cabergoline reduced prolactin levels and increased estradiol levels in all study groups, the effect on prolactin was more pronounced in groups B and C compared to group A. In groups B and C, the drug enhanced glucose homeostasis, increased HDL-cholesterol, and decreased triglycerides, hsCRP, fibrinogen, homocysteine, uric acid, and UACR. In group A, only insulin resistance, hsCRP, and homocysteine were reduced by cabergoline. The effects on insulin sensitivity, HDL-cholesterol, triglycerides, hsCRP, fibrinogen, homocysteine, uric acid, and UACR were proportional to the decrease in prolactin and baseline levels of 25-hydroxyvitamin D. The obtained results suggest that vitamin D status determines cabergoline’s cardiometabolic effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, 40-752 Katowice, Poland.
ORCID-Profile: Robert Krysiak, Marcin Basiak, Bogusław Okopień
Förderung
- Medical University of Silesia in Katowice
Zitieren
APA
Krysiak, R., Basiak, M., Machnik, G., Szkróbka, W., & Okopień, B. (2023). Vitamin D Status Determines Cardiometabolic Effects of Cabergoline in Women with Elevated Prolactin Levels: A Pilot Study. Nutrients. https://doi.org/10.3390/nu15102303
Vancouver
Krysiak R, Basiak M, Machnik G, Szkróbka W, Okopień B. Vitamin D Status Determines Cardiometabolic Effects of Cabergoline in Women with Elevated Prolactin Levels: A Pilot Study. Nutrients. 2023. doi:10.3390/nu15102303
BibTeX
@article{Krysiak2023,
author = {Krysiak, Robert and Basiak, Marcin and Machnik, Grzegorz and Szkróbka, Witold and Okopień, Bogusław},
title = {Vitamin D Status Determines Cardiometabolic Effects of Cabergoline in Women with Elevated Prolactin Levels: A Pilot Study},
journal = {Nutrients},
year = {2023},
doi = {10.3390/nu15102303}
}
EUVIMED